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Navigate: a study protocol for a
randomised controlled trial of an online
treatment decision aid for men with low-
risk prostate cancer and their partners
Penelope Schofield1,2,3,4* , Karla Gough2,5, Amelia Hyatt2, Alan White2, Mark Frydenberg6,7,
Suzanne Chambers8,9,10,11, Louisa G. Gordon12,13,14, Robert Gardiner15,16, Declan G. Murphy3,17,
Lawrence Cavedon18, Natalie Richards2, Barbara Murphy19,20, Stephen Quinn21 and Ilona Juraskova22
Abstract
Background: Active surveillance (AS) is the disease management option of choice for low-risk prostate cancer.
Despite this, men with low-risk prostate cancer (LRPC) find management decisions distressing and confusing. We
developed Navigate, an online decision aid to help men and their partners make management decisions consistent
with their values. The aims are to evaluate the impact of Navigate on uptake of AS; decision-making preparedness;
decisional conflict, regret and satisfaction; quality of illness communication; and prostate cancer-specific quality of
life and anxiety. In addition, the healthcare cost impact, cost-effectiveness and patterns of use of Navigate will be
assessed. This paper describes the study protocol.
Methods: Three hundred four men and their partners are randomly assigned one-to-one to Navigate or to the
control arm. Randomisation is electronically generated and stratified by site. Navigate is an online decision aid that
presents up-to-date, unbiased information on LRPC tailored to Australian men and their partners including each
management option and potential side-effects, and an interactive values clarification exercise. Participants in the
control arm will be directed to the website of Australia’s peak national body for prostate cancer. Eligible patients
will be men within 3 months of being diagnosed with LRPC, aged 18 years or older, and who are yet to make a
treatment decision, who are deemed eligible for AS by their treating clinician and who have Internet access and
sufficient English to participate. The primary outcome is self-reported uptake of AS as the first-line management
option. Secondary outcomes include self-reported preparedness for decision-making; decisional conflict, regret and
satisfaction; quality of illness communication; and prostate cancer-specific quality of life. Uptake of AS 1 month after
consent will be determined through patient self-report. Men and their partners will complete study outcome
measures before randomisation and 1, 3 and 6 months after study consent.
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Discussion: The Navigate online decision aid has the potential to increase the choice of AS in LRPC, avoiding or
delaying unnecessary radical treatments and associated side effects. In addition, Navigate is likely to reduce patients’
and partners’ confusion and distress in management decision-making and increase their quality of life.
Trial registration: Australian and New Zealand Clinical Trial Registry ACTRN12616001665426. Registered on 2
December 2016. All items from the WHO Trial Registration Data set can be found in this manuscript.
Keywords: Low-risk prostate cancer, Decision aid, Management decision, Treatment decision, Active surveillance,
RCT, Distress, Quality of life
Background
Prostate cancer is one of the most commonly diagnosed
cancers on a global scale, with incidence rates of 1.1 mil-
lion during 2012 alone [1]. The vast majority of cases are
detected within high-income regions such as Australia,
New Zealand, Northern America and Western and North-
ern Europe. The high incidence rates have been attributed
to the widespread use of prostate-specific antigen (PSA)
testing [2]. Fortunately, the majority of prostate cancers
are localised at the time of diagnosis [3]. Although early
detection strategies can reduce the risk of disease progres-
sion, they can also result in overtreatment, particularly in
men diagnosed with low-risk prostate cancer (LRPC).
Men diagnosed with LRPC may be offered curative treat-
ment options, including radical prostatectomy (RP), radio-
therapy (RT) and brachytherapy (BT), or may be managed
with routine monitoring called active surveillance (AS). It is
estimated that up to 50% of all prostate cancer cases do not
require curative treatment up to 12 years post-diagnosis [4].
Indeed, evidence suggests that there is no survival benefit
in providing curative treatments for LRPC at least up to 10
years after diagnosis [5, 6]. Moreover, these curative treat-
ment options are commonly associated with both short-
and long-term side effects such as erectile dysfunction,
urinary and bowel incontinence and reduced quality of life
[6–8]. This underscores the importance of patient involve-
ment in decision-making regarding the commencement of
curative treatment during early-stage disease [9].
AS is now recommended as a preferred management strat-
egy for LRPC [9–13], although rates of AS uptake vary widely
around the world [14]. AS is a proactive approach which aims
to delay or avoid radical treatments through close monitoring
of both the patient and the tumour [15]. AS is now widely ac-
cepted as an effective management strategy for LRPC, and cli-
nicians are encouraged to offer AS to eligible patients [9, 13,
16, 17]. AS has also been shown to be the least costly option
for LRPC and increased uptake of AS would lead to substan-
tial cost-savings to the health system [18].
Comparisons in outcomes between management options
for LRPC
A recent examination of cancer mortality statistics re-
vealed a 15-year survival rate of 95% for men with LRPC
on AS [19]. In terms of age-specific outcomes for AS,
15-year cancer-specific mortality has been shown to be
5.7% for men aged 65–74 years and 10% for those over
75 [20]. Indeed, 10-year prostate cancer-specific mortal-
ity rates have been shown to be similar regardless of
whether men undergo AS, RT or RP [6]. However, re-
cent data has raised concerns about compliance with AS
protocols, reporting that 75% of patients do not meet
minimum requirements for PSA testing and biopsies to
ensure that their cancer is adequately monitored [21].
While survival rates remain similar across management
options, impacts on urinary, bowel and sexual function vary
significantly. Two recent studies demonstrated significantly
greater urinary incontinence and poorer sexual function in
men treated with RP compared with those managed by AS
[7, 22]. Importantly, men receiving AS report similar out-
comes in relation to sexual, urinary and bowel function as
men who are not diagnosed with LRPC [7].
Treatment decision making in LRPC
Management decision making is difficult for men with
LRPC. Decision-related distress and confusion are high
[23–25], due largely to the variety of management options
with no clear best choice and the fact that management
decisions are highly dependent on men’s individual prefer-
ences and lifestyle [26]. For those contemplating AS, anx-
iety about not receiving radical (i.e. curative) treatment is
common [24]. Most men do not consider all management
options nor do they make decisions concordant with their
personal preferences and values [27, 28]. Partners of men
with LRPC also experience high decisional distress and
confusion [15, 29], and some pressure their partner to-
wards curative treatment [24, 28]. The study anticipates
that both men and their partners would benefit from
decision-making support, particularly regarding their un-
derstanding of the benefits and risks associated with each
management option, the risk of the LRPC spreading out-
side the prostate and the concordance of each option with
their personal values and preferences [27].
Decision aids for LRPC
Decision aids are textual, audio, visual and web-based
tools that provide evidence-based information to assist
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patients to consider management options within the
context of their own preferences and values. Decision
aids guide patients through a deliberative process of ac-
tively weighing-up the benefits/costs of available treat-
ment options, thus enabling decision-making that is
both evidence-based and considerate of patient prefer-
ences and life circumstances [30]. A 2017 Cochrane sys-
tematic review demonstrated that decision aids improve
knowledge of available treatment options and outcomes,
and accuracy of risk perceptions, decrease decisional
conflict, increase decisional satisfaction, increase congru-
ency between treatment choice and patient values and
improve patient-clinician communication [31]. Level I
evidence shows that decision aids reduce the proportion
of those who choose surgery in favour of less invasive
management options [13].
Several decision aids for LRPC exist, and some of these
have shown promise in assisting in decision-making and
reducing decisional regret [32–35]. However, two sys-
tematic reviews have concluded that none comprehen-
sively addresses the needs of men with LRPC [26, 27].
The major deficits include incomplete or biassed con-
tent, lack of consideration of patient values, inadequate
partner involvement, lack of clarification between AS
and watchful waiting (WW), lack of theoretical frame-
work, too few examples of patient experiences and inad-
equate systematic evaluation [26, 27]. Both reviews
highlighted an urgent need for high-quality decision
aids, which accurately portray AS and are developed in
line with International Patient Decision Aid Standards
(IPDAS) [26, 27]. Moreover, none of the currently avail-
able decision aids have been tailored to the local health
care context or are easily accessible by Australian men.
Navigate—an Australian online treatment decision aid for
LRPC
Besides doctors, the Internet is the primary source of in-
formation for men with prostate cancer [36]. In 2017,
86% of Australian households had Internet access at
home [37] while 88% of Australian adults aged 18–75
owned or had access to a smartphone [37]. Provision of
an online decision aid enables access from home, pro-
motes rapid and widespread dissemination and enables
easy updating to ensure currency of content.
We have developed the Navigate online decision aid
which presents up-to-date, unbiased information tailored
to Australian men with LRPC in written, graphical and
video formats. The Navigate decision aid was informed
by a qualitative study which explored the experiences of
21 men with LRPC who had been on AS for at least 3
months, and 14 of their partners [24]. The findings con-
firmed that partners were highly involved in manage-
ment decision-making and highlighted the need for
consistent and accurate discourse surrounding LRPC
diagnosis and management options. Men and their part-
ners emphasised the need for balanced information to fa-
cilitate informed and values-based treatment decisions [24].
Navigate was co-designed by consumers and a multidis-
plinary team, is evidence-based and theoretically under-
pinned and complies with IPDAS criteria. Table 1 displays
the key features of the website and example graphic images.
Methods
Study aims and hypotheses
The aims of this study are to evaluate the impact of
Navigate for men with low-risk prostate cancer and their
partners on uptake of AS as a first-line management op-
tion; men’s preparedness for decision-making; men’s de-
cisional conflict, regret and satisfaction; the quality of
men’s illness communication; and men’s prostate
cancer-specific quality of life. The secondary aims are to
estimate study arm differences in men’s anxiety; explore
the impact of Navigate on partner’s decisional conflict,
regret and satisfaction, and quality of illness communi-
cation; assess the healthcare cost impact and cost-
effectiveness of Navigate (economic sub-study); and de-
termine the specific patterns of use of Navigate (web
analytic sub-study).
Specific hypotheses are that a higher proportion of
men randomised to Navigate will select AS as a first-line
management option when compared with men rando-
mised to the control group, and men randomised to
Navigate will feel better prepared for decision-making,
experience lower levels of decisional conflict and regret
and higher levels of decisional satisfaction and report
better quality of illness communication and better pros-
tate cancer-specific quality of life when compared to
men randomised to the control group.
Research questions, rather than hypotheses, were de-
veloped for secondary aims, since no specific predictions
were made. Research questions relevant to the main
study include:
Do men randomised to Navigate report higher or lower
levels of anxiety than men in the control group?
Do the partners of men randomised to Navigate experi-
ence lower levels of decisional conflict and regret, and
higher levels of decisional satisfaction when compared
with the partners of men randomised to the control
group?
The research question for the economic sub-study is:
What is the cost-effectiveness of the decision-aid inter-
vention compared with usual care for men newly diag-
nosed with prostate cancer?
The research questions for the web analytic study
include:
What are the general patterns of use of the website; are
there any identifiable areas for improvement from a user
experience perspective?
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Do men diagnosed with prostate cancer use the website
differently compared with partners of these men?
What are the patterns of use across individuals relating
to the values clarification exercise?
Do patterns of use relate to the primary and secondary
outcome variables?
Trial design and randomisation
This study will use a parallel group, prospective rando-
mised controlled trial (RCT) with one baseline and three
post-baseline assessments (i.e. follow-ups 1, 2 and 3),
along with economic and web analytics substudies. In
this study, ‘partner’ refers to the support person nomi-
nated by the patient. Both patients and their partners (if
one is nominated) will be invited to participate. Follow-
ing informed consent and completion of baseline study
measures, participating patients and their partners will
be randomly assigned to Navigate or the usual care arm
with a one-to-one allocation, stratified by recruitment
site. Randomisation will be undertaken remotely and in-
dependently by the trial coordinator using a purpose-
built Microsoft Access randomisation database. After a
participant (patient/partner) has been enrolled and com-
pleted baseline measures, the trial coordinator uses the
randomisation database to assign the participant to the
intervention or usual care arm and informs them via
email of the experimental allocation. Post-baseline as-
sessments will occur approximately 1, 3 and 6 months
after consent. Participants will be informed of their allo-
cation after completing baseline questionnaires. Re-
searchers involved in data collection will be blinded to
group allocation. Statisticians will be unblinded to allo-
cation before preparation of the participant flow diagram
and outcome analysis. Ethical approval was received
from the Peter MacCallum Cancer Centre Human Re-
search Ethics Committee (HREC16 PMCC114). Figure 1
displays the enrolment, group allocation, intervention
and assessment schedule.
Participants and study setting
Australian patients will be eligible to participate regard-
less of whether or not their partners participate, whereas
partners are not eligible without a participating patient.
Eligibility criteria
Men will be eligible to participate in this trial if they are
18 years or older; have been diagnosed with LRPC in the
last 3 months and have yet to make a treatment deci-
sion; have been deemed eligible for AS by their treating
clinician; and have Internet access and sufficient English
to complete study requirements and use the Navigate
website. Men will be ineligible if they have a severe psy-
chiatric or cognitive disorder or are too unwell to
Table 1 Key features of the Navigate online decision aid
Schofield et al. Trials           (2021) 22:49 Page 4 of 12
participate as deemed by their treating clinician, self-
report, or the research team at the time of approach.
Partners are eligible to participate in this trial if they
are 18 years or older, are the designated partner identi-
fied by the consenting patient and have Internet access
and sufficient English to complete study requirements
and use the Navigate website.
Participating sites include five Australian treatment
centres within Victoria (Peter MacCallum Cancer
Centre, Western Hospital, Cabrini Hospital, Alfred Hos-
pital, Austin Hospital) and two in Queensland (Royal
Brisbane and Women’s Hospital, Redcliffe Hospital).
Men with LRPC and their partners from either public or
private health care settings are also able to self-refer on-
line to the trial.
Intervention
Intervention participants are emailed login details to ac-
cess the Navigate online decision aid which is hosted on
the Prostate Cancer Foundation of Australia website.
Using Navigate, men and their partners are led through
information on each treatment option for LRPC with its
potential benefits and side-effects. An interactive values
clarification exercise assists the men with weighing up
the advantages and disadvantages of each management
option to clarify what matters to them and to guide their
preferences.
Usual care
Usual care participants are provided with minimal infor-
mation to fulfil ethical obligations and emailed a link to
the Prostate Cancer Foundation of Australia website
page for LRPC treatments. This website provides brief
information on LRPC and treatment options, but differs
from the Navigate website in that it does not include
comparisons of the pros and cons of each management
option, a values clarification exercise, nor the presenta-
tion of material in graphical or multimedia formats.
Recruitment and consent
Potentially eligible men will (i) be identified by their
treating clinician/nurse or the site investigator using
screening clinic lists or (ii) self-refer to the website via
digital marketing strategies. The treating clinician can
also refer interested patients directly to the study team.
Once men and their partners provide consent and
complete baseline questionnaires, they are provided with
the appropriate website link as per their group alloca-
tion. Non-consenters are asked for de-identified demo-
graphic and clinical details. Attrition will be monitored
and reasons for withdrawal recorded.
Hospital recruitment and consent
Eligible men are approached after their diagnosis by re-
search nurse/assistant, consistent with the agreement of
those patients’ treating doctors. The research nurse/as-
sistant reviews the Patient Information and Consent
Form (PICF) with interested patients and patients pro-
vide online consent via the Qualtrics survey platform.
Using the same consent procedure, partners are invited
to participate. Consenting patients are also asked to pro-
vide written consent for the study team to obtain data
from the Medicare Benefits Scheme and Pharmaceutical
Benefits Scheme databases.
For patients or partners who are unsure about partici-
pating or do not have time to complete the PICF in
clinic, a research team member is able to contact the pa-
tient/partner by telephone within a week to determine
participation status. If the patient/partner agrees to par-
ticipate, they are emailed a personalised PICF link.
Self-referral, recruitment and consent
The study is being promoted using digital marketing and
community engagement strategies (Google Ads, Face-
book, social media, blogs, commentary articles). Men
who self-refer to the study are asked to complete an on-
line Expression of Interest form including the details of
their treating clinician who will be contacted by the
study team to confirm eligibility. If eligible, a research
nurse/assistant will undertake the consent process with
the patient over the telephone.
Clinician referral, recruitment and consent
The treating clinician can also refer their patients dir-
ectly the study confirming they meet the eligibility cri-
teria and they have discussed the trial with his/her
patient who is happy to be contacted. A research nurse/
assistant is then available to undertake the consent
process with the patient over the telephone.
Procedure and assessments
After consent, the research team emails a link to access
this questionnaire to be completed at home. The online
questionnaires were created by the research team within
Qualtrics, an online program which prevents skipping
questions. A reminder telephone call is made if the study
measures have not been completed within 48 h. How-
ever, if the participant exits the form without completing
the entire questionnaire, they are not followed up to ob-
tain the remaining data.
Follow-ups 1, 2 and 3 are emailed to participants re-
spectively at 1, 3 and 6months post-consent. If follow-
up questionnaires have not been completed within
2 weeks, a reminder telephone call is made. After com-
pletion of follow-up 3, participants are contacted via
email and telephone to confirm trial completion and to
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thank the participant for their time. The trial flow chart
is presented in Fig. 2.
Main study measures
Demographic and clinical information
Demographic information collected from patients and
partners includes age (in years), marital status, postcode,
highest education level, occupation and ethnic origin.
Clinical information (Gleason score and PSA) is ob-
tained from the referring site or the referring clinician or
collected via a medical record audit.
Primary outcome
The primary outcome is self-reported uptake of AS as
the first-line management option for LRPC assessed as a
percentage (AS or curative treatment option) at follow-
up 1.
Secondary outcomes
Preparedness for decision-making is assessed at follow-up
1 with the preparedness for decision-making scale
(PrepDM). The PrepDM total scale measures the per-
ceived usefulness of the decision aid in preparing the pa-
tient to communicate with his doctor(s) to make a
health decision and has shown acceptable internal
consistency (Cronbach’s α = 0.92 to 0.96), and Item Re-
sponse Theory analyses demonstrated that all ten scale
items function well [38].
Decisional conflict is assessed at follow-up 1 with the
16-item Decisional Conflict Scale (DCS). The DCS
Fig. 1 Enrolment, group allocation, intervention and assessment schedule. Note: DA, decision aid; PCFA, Prostate Cancer Foundation of Australia
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Fig. 2 Study trial flow chart
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measures patients’ perceptions of uncertainty, being un-
informed and unsupported and having unclear values in
decision making. The DCS is suitable for use with cancer
patients and has shown acceptable internal consistency
(Cronbach’s α = 0.78–0.92), test-retest reliability (r =
0.81) and responsiveness (longitudinal validity) [39].
Decisional satisfaction is assessed at follow-up 2 and,
for patients only, follow-up 3 with the 6-item Satisfac-
tion with Decision (SWD) measure. The SWD has
shown acceptable internal consistency (Cronbach’s α =
0.86), discriminant validity and responsiveness [31, 40].
Decisional regret is assessed at follow-up 2 and, for pa-
tients only, follow-up 3 with the 5-item Decisional Re-
gret Scale (DRS). The DRS has shown acceptable
internal consistency (Cronbach’s α = 0.81–0.92) and con-
vergent validity with related measures (r = 0.31–0.60)
and responsiveness [31].
The quality of men’s and partners’ illness communica-
tion is assessed at baseline and follow-up 1 with the 4-
item Couples’ Illness Communication Scale (CICS). The
CICS was adapted for use in prostate cancer popula-
tions. The original scale has shown acceptable internal
consistency (Cronbach’s α = 0.80) and convergent valid-
ity with other measures of dyadic adjustment [41].
Anxiety is assessed at baseline and follow-up 1 with
the 7-item PROMIS Emotional distress-Anxiety 7a
short-form. The Anxiety 7a is a standardised, valid and
precise measure specifically developed for use in clinical
oncology research [42].
Prostate cancer-specific quality of life is assessed at
baseline and every follow-up with the 26-item Expanded
Prostate Cancer Index Composite short-form (EPIC-26).
The EPIC-26 comprises four subscales: urinary, bowel,
sexual and hormonal. The hormonal subscale is not rele-
vant in this context, so will not be administered. Sub-
scales have shown acceptable internal consistency (all
Cronbach’s α > 0.70), test-retest reliability (all r > 0.69)
and responsiveness when used independently [43].
Sample size
The sample size calculation was based on 80% power, a
two-sided α = 0.05 test, and a difference in uptake of the
AS treatment option of 15%. Assuming 65% uptake in
the usual care group [3] and 80% uptake in the interven-
tion group (a conservative assumption), the required
sample size is 272 patients (136 in each study arm). Our
sample size calculation was performed with PASS ver-
sion 16. Allowing for 10% attrition, a total sample size of
304 participants is required.
Statistical analysis
All analyses will be performed using Stata 16. Prior to
formal analysis, descriptive statistics and graphical dis-
plays will be used to identify missing and out-of-range
values, assess distributional assumptions and identify
outliers.
Recruitment bias will be assessed by comparing demo-
graphic and clinical characteristics of consenters and
non-consenters using t tests (or Mann-Whitney) and
chi-squared (or Fisher’s exact) tests as appropriate. Dif-
ferential attrition will be assessed by comparing baseline
characteristics of drop-outs and continuing participants
using the same statistical tests.
Outcome analysis
The primary analysis will follow the intention-to-treat
principle and all study participants will be analysed as
part of the study arm to which they were randomised
in all outcome analysis. Missing data will be imputed
using multiple imputation, redrawing 50 samples.
Pearson’s chi squared test will be used to analyse
study arm differences in the primary outcome. Linear
regression will be used to analyse study arm differ-
ences for preparedness for decision-making at follow-
up 1, illness communication at follow-up 1 and anx-
iety at follow-up. Each model will be adjusted for
baseline and group assignment. Decisional conflict
(follow-up 1), satisfaction (follow-ups 2 and 3) and
regret (follow-ups 2 and 3) will be analysed using lin-
ear regression with group assignment as the inde-
pendent covariate (equivalent to a test). The effect
between groups and significance will be assessed
using the beta-coefficient and p value corresponding
to the group assignment term. Finally, prostate
cancer-specific quality of life will be analysed with a
random effects mixed model. The independent vari-
ables will be group assignment, time (coded 0/1) and
the interaction term group assignment BY time. The
effect and between groups and significance will be
assessed using the beta-coefficient and p value corre-
sponding to the interaction term. All results will be
presented with 95% confidence intervals and a p value
less than 0.05 (two-sided) will be deemed to be statis-
tically significant.
Exploratory analyses
Participants will be analysed as part of the study arm to
which they were randomised in all exploratory analysis.
Regression (similar to the above) will be used to analyse
study arm differences in the following exploratory out-
comes: men’s anxiety (at follow-up 1), partners’ illness
communication with men (at follow-up 1), partners’ de-
cisional conflict (follow-up 1), partner’s satisfaction (fol-
low-ups 2 and 3) and partner’s regret (follow-ups 2 and
3). The effect between groups and significance will be
assessed using the beta-coefficient and p value corre-
sponding to the group assignment term.
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Health-economic sub-study
The aim of the economic sub-study is to assess the fi-
nancial burden and cost-effectiveness of the Navigate
online decision aid in the Australian context. This will
compare the costs and patient outcomes of intervention
versus usual care aligning to the goals of the planned
RCT. The analysis will take a societal perspective and in-
clude Medicare data for all patient participants to assess
healthcare costs to government and patient out-of-
pocket expenses from participant surveys.
Health utility data will be collected at baseline and
follow-ups 2 and 3. The 5-item EuroQol-5D (EQ-5D-5L)
will be used, which is a standardised measure of health
status developed specifically for economic evaluation
and is suitable for cancer patients. It has shown accept-
able internal consistency (Cronbach’s α = 0.71), test-
retest reliability (kappa = 0.7), convergent validity (r >
0.49), discriminant validity and responsiveness [44, 45].
Patient health care costs will be reported by patients at
follow-ups 2 and 3. These include out-of-pocket ex-
penses for all medical services, as well as costs for travel,
accommodation and income lost from interrupted em-
ployment. The Patient Costs Questionnaire (PCQ) is
purpose-built for Australian men with prostate cancer
[46] and includes items such as general practice and spe-
cialist visits, counselling and support services and sexual
and incontinence aids. Follow-up 3 will also include the
COST-FACIT questionnaire [47] capturing financial
hardship and additional questions used previously by
men with prostate cancer relating to early retirement
and financial situation.
At the end of the data collection period, Medicare data
on all services and medicines for all consenting partici-
pants will be accessed. With this data, the types and dol-
lar amounts exchanged for health services, community
services and medicines for prostate cancer and other dis-
eases will be assessed, including medical services for
privately-insured patients. The main economic outcome
will be incremental cost per quality-adjusted life year for
the Navigate tool versus usual care. Methods for this
economic evaluation will be governed by standardised
guidelines in modelling studies and economic evalua-
tions [48, 49].
Web analytics sub-study
Website analytics will be used to indicate preferred
modes of interaction, which aspects users (participants)
find most engaging and how users prefer to access infor-
mation on the Navigate website. This provides indicative
answers to specific questions, such as how comprehen-
sively users consume the information regarding the dif-
ferent management options before submitting
preferences on decisions. Analysis of user behaviour may
lead to a better understanding of the effectiveness of the
decision tool, as well as potentially identifying areas for
improvement. Planned data capture includes click infor-
mation, pages visited, time spent on each page, informa-
tion viewed and/or downloaded and values clarification
exercise responses. Since data is associated with user ID,
behaviours can be linked to demographic characteristics
such as age, sexual orientation, or user type (i.e. patient
or partner).
Analysis will be restricted to the intervention group of
the randomised study since the focus of this sub-study is
the characteristics and effectiveness of the web-based de-
cision tool. Effects to be investigated include informa-
tional value of pages (determined by number of visits
and time spent), as well as complex behavioural effects
such as the amount of information consumed before
coming to decisions. Variance across demographic sub-
groups will be measured using appropriate statistical
metrics (e.g. ANOVA, chi-squared) to determine
demographic-based preferences. Data mining techniques
(e.g. association-rule mining) will be applied to attempt
to determine other associations between behaviour char-
acteristics (e.g. consuming certain information leading to
certain decisions and/or outcomes).
Data storage, management and future use
All data is kept in password-protected databases. Non-
identifiable participant data is separated from databases
linking names with participant identifiable details. Once
the study is completed, this database with identifiable
details will be destroyed; the remaining data will be
retained indefinitely. With the exception of the Medicare
data, participants who consent to this study will also be
consenting to the use of their data for future unspecified
research. To obtain access to the data obtained through
this project, investigators will have to have their projects
approved by the HREC of their host institution and by
Peter Mac Cancer Centre HREC.
Discussion
With the increase in diagnoses of LRPC [1, 50], there is an
urgent need for resources to support patients and their
partners in their management decision making and, spe-
cifically, to reduce the choice of potentially unnecessary
radical treatments with inherent significant side effects
[26, 27]. Confusion, anxiety, distress and decisional regret
are common in men with LRPC [23–25] and in their part-
ners which may be enduring [15, 24, 28, 29]. Indeed, men
with LRPC and their partners express the need for un-
biased information about potential benefits and risks of
their management options, to help them informed deci-
sions which are aligned their own personal preferences
and values [24].
The Navigate online decision aid has the potential to
increase the choice of AS to manage LRPC, thereby
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avoiding or delaying radical treatments. In addition,
Navigate has the potential to reduce patients’ and part-
ners’ confusion and distress in management decision
making, reduce decisional regret, increase decision-
making preparedness and decisional satisfaction and im-
prove prostate cancer-specific quality of life. Navigate
will be made available to all Australian men diagnosed
with LRPC to support their management decision
making.
Besides the potential ramifications on quality of
life for men who receive treatment with curative in-
tent, management of LRPC exerts a substantial fi-
nancial burden to governments, hospitals and men
affected by this condition which is increasing annu-
ally [18]. Approximately 25% of Australian prostate
cancer patients diagnosed have LRPC [3, 11]: ap-
proximately 5500 per year. If this intervention is
successful in achieving the minimal expected differ-
ence of 15%, which represents 825 men selecting AS
in preference to the most common definitive treat-
ment approach (i.e. radical prostatectomy), this could
present an annual cost saving of at least AU$6.1 mil-
lion to Australians (difference in average cost per
patient of AU$1400 for government and AU$2300
for out of pocket) [18]. As prostate cancer diagnoses
and health care costs escalate, these projected cost savings
will grow. Therefore, this project has the potential to re-
duce both the financial costs to the government and per-
sonal costs to the large and growing population of men
with LRPC.
The findings of this study will be disseminated via
publications in peer-reviewed journals and by engage-
ment with clinicians, media, government and consumers.
In particular, we will promote the outcomes of this study
amongst the broader medical and consumer community
to improve treatment paradigms and approaches to sup-
portive care for patients with LRPC and their partners.
This will include providing the Navigate online decision
aid as standard care for patients diagnosed with prostate
cancer via the Prostate Cancer Foundation of Australia
website, if ultimately proved effective.
Trial status
The protocol version number is HREC16PMCC114_
NAVIGATE_Protocol_V8_27/03/2020. Patient recruit-
ment opened on May 2017, and it is estimated that it
will cease in December 2020.
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